MX2020011882A - Compuestos de 1h-indazole-3-carboxamida como inhibidores de glucogeno sintasa cinasa 3 beta. - Google Patents
Compuestos de 1h-indazole-3-carboxamida como inhibidores de glucogeno sintasa cinasa 3 beta.Info
- Publication number
- MX2020011882A MX2020011882A MX2020011882A MX2020011882A MX2020011882A MX 2020011882 A MX2020011882 A MX 2020011882A MX 2020011882 A MX2020011882 A MX 2020011882A MX 2020011882 A MX2020011882 A MX 2020011882A MX 2020011882 A MX2020011882 A MX 2020011882A
- Authority
- MX
- Mexico
- Prior art keywords
- indazole
- disorders
- glycogen synthase
- synthase kinase
- carboxamide compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18171084 | 2018-05-07 | ||
| PCT/EP2019/061532 WO2019215075A1 (en) | 2018-05-07 | 2019-05-06 | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020011882A true MX2020011882A (es) | 2021-01-20 |
Family
ID=62134122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011882A MX2020011882A (es) | 2018-05-07 | 2019-05-06 | Compuestos de 1h-indazole-3-carboxamida como inhibidores de glucogeno sintasa cinasa 3 beta. |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US11472795B2 (enExample) |
| EP (1) | EP3790873B1 (enExample) |
| JP (1) | JP7411574B2 (enExample) |
| KR (1) | KR102778690B1 (enExample) |
| CN (1) | CN112135821B (enExample) |
| AU (1) | AU2019265606B2 (enExample) |
| BR (1) | BR112020021922A2 (enExample) |
| CA (1) | CA3094896A1 (enExample) |
| CY (1) | CY1125293T1 (enExample) |
| DK (1) | DK3790873T3 (enExample) |
| EA (1) | EA202092422A1 (enExample) |
| ES (1) | ES2913975T3 (enExample) |
| GE (2) | GEP20227437B (enExample) |
| HR (1) | HRP20220664T1 (enExample) |
| HU (1) | HUE058894T2 (enExample) |
| IL (1) | IL278330B2 (enExample) |
| LT (1) | LT3790873T (enExample) |
| MA (1) | MA52557A (enExample) |
| MD (1) | MD3790873T2 (enExample) |
| MX (1) | MX2020011882A (enExample) |
| PL (1) | PL3790873T3 (enExample) |
| PT (1) | PT3790873T (enExample) |
| RS (1) | RS63255B1 (enExample) |
| SG (1) | SG11202009230WA (enExample) |
| SI (1) | SI3790873T1 (enExample) |
| SM (1) | SMT202200227T1 (enExample) |
| UA (1) | UA128089C2 (enExample) |
| WO (1) | WO2019215075A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4079732A4 (en) * | 2019-12-16 | 2023-10-18 | Korea Research Institute of Chemical Technology | NEW INDAZOLE DERIVATIVE AND ITS USE |
| CN114230565B (zh) * | 2020-09-09 | 2023-10-27 | 成都奥睿药业有限公司 | 5-取代吲哚3-酰胺衍生物及其制备方法和用途 |
| JP7746384B2 (ja) * | 2020-12-08 | 2025-09-30 | ディスアーム セラピューティクス， インコーポレイテッド | Ｓａｒｍ１のベンゾピラゾール阻害剤 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0667867A1 (en) | 1992-11-05 | 1995-08-23 | Smithkline Beecham Plc | Piperidine derivatives as 5-ht4 receptor antagonists |
| GB0218625D0 (en) | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
| ITMI20030287A1 (it) | 2003-02-18 | 2004-08-19 | Acraf | Indazolammidi dotate di attivita' analgesica metodo, per |
| ITMI20030972A1 (it) | 2003-05-15 | 2004-11-16 | Acraf | Indazolo dotato di attivita' analgesica, metodo per prepararlo e composizione farmaceutica che lo comprende. |
| KR101061599B1 (ko) * | 2008-12-05 | 2011-09-02 | 한국과학기술연구원 | 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물 |
| TW201040191A (en) | 2009-03-27 | 2010-11-16 | Abbott Gmbh & Co Kg | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| IN2014CN02646A (enExample) * | 2011-09-14 | 2015-08-07 | Samumed Llc | |
| BR112014018657B1 (pt) | 2012-02-21 | 2022-08-02 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A | Compostos de 1h-indazol-3-carboxamida |
| AU2013224302B2 (en) | 2012-02-21 | 2017-03-30 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
| CN106535890A (zh) | 2014-03-20 | 2017-03-22 | 萨穆梅德有限公司 | 5‑取代的吲唑‑3‑羧酰胺及其制备和应用 |
| EP3755696B1 (en) * | 2018-02-23 | 2023-04-05 | BioSplice Therapeutics, Inc. | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof |
-
2019
- 2019-05-06 ES ES19721295T patent/ES2913975T3/es active Active
- 2019-05-06 CA CA3094896A patent/CA3094896A1/en active Pending
- 2019-05-06 RS RS20220482A patent/RS63255B1/sr unknown
- 2019-05-06 HR HRP20220664TT patent/HRP20220664T1/hr unknown
- 2019-05-06 MA MA052557A patent/MA52557A/fr unknown
- 2019-05-06 SI SI201930227T patent/SI3790873T1/sl unknown
- 2019-05-06 GE GEAP201915506A patent/GEP20227437B/en unknown
- 2019-05-06 DK DK19721295.4T patent/DK3790873T3/da active
- 2019-05-06 EP EP19721295.4A patent/EP3790873B1/en active Active
- 2019-05-06 PL PL19721295T patent/PL3790873T3/pl unknown
- 2019-05-06 KR KR1020207030163A patent/KR102778690B1/ko active Active
- 2019-05-06 SM SM20220227T patent/SMT202200227T1/it unknown
- 2019-05-06 LT LTEPPCT/EP2019/061532T patent/LT3790873T/lt unknown
- 2019-05-06 MX MX2020011882A patent/MX2020011882A/es unknown
- 2019-05-06 US US17/051,352 patent/US11472795B2/en active Active
- 2019-05-06 SG SG11202009230WA patent/SG11202009230WA/en unknown
- 2019-05-06 PT PT197212954T patent/PT3790873T/pt unknown
- 2019-05-06 MD MDE20210228T patent/MD3790873T2/ro unknown
- 2019-05-06 HU HUE19721295A patent/HUE058894T2/hu unknown
- 2019-05-06 EA EA202092422A patent/EA202092422A1/ru unknown
- 2019-05-06 GE GEAP202215506A patent/GEAP202215506A/en unknown
- 2019-05-06 CN CN201980029405.9A patent/CN112135821B/zh active Active
- 2019-05-06 UA UAA202006085A patent/UA128089C2/uk unknown
- 2019-05-06 BR BR112020021922-3A patent/BR112020021922A2/pt unknown
- 2019-05-06 AU AU2019265606A patent/AU2019265606B2/en active Active
- 2019-05-06 WO PCT/EP2019/061532 patent/WO2019215075A1/en not_active Ceased
- 2019-05-06 JP JP2020562568A patent/JP7411574B2/ja active Active
- 2019-05-06 IL IL278330A patent/IL278330B2/en unknown
-
2022
- 2022-05-26 CY CY20221100366T patent/CY1125293T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX351287B (es) | Compuestos de 1h-indazol-3-carboxamida como inhibidores de glucogeno sintasa quinasa 3 beta. | |
| MX2022001295A (es) | Inhibidores de kif18a. | |
| MX2025003987A (es) | Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos | |
| TN2019000192A1 (en) | Pyrazole derivatives as malt1 inhibitors | |
| MX2020006587A (es) | Derivados de aminopiridina como inhibidores de fosfatidilinositol fosfato cinasa. | |
| PH12017501669A1 (en) | Alpha-cinnamide compounds and compositions as hdac8 inhibitors | |
| MX2020006613A (es) | Derivados de aril-bipiridina amina como inhibidores de fosfatidilinositol fosfato cinasa. | |
| MX351288B (es) | Uso de compuestos de 1h-indazol-3-carboxamida como beta inhibidores de glucogeno sintasa quinasa 3 beta. | |
| EP3778605A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
| PH12012501768A1 (en) | Piperidin-4-yl azetidine derivatives as jak1 inhibitors | |
| PH12021550324A1 (en) | 5 to 7 membered heterocyclic amides as jak inhibitors | |
| MY199446A (en) | Compounds and compositions and uses thereof | |
| MX2020009228A (es) | Compuestos diolicos de aminopirazina como inhibidores de fosfoinositida 3-cinasas-gamma. | |
| SA521422152B1 (ar) | Vanin مركبات عطرية غير متجانسة كمثبطات | |
| EP4335512A3 (en) | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | |
| PH12018501567A1 (en) | New substituted cyanoindoline derivatives as nik inhibitors | |
| MX2020011882A (es) | Compuestos de 1h-indazole-3-carboxamida como inhibidores de glucogeno sintasa cinasa 3 beta. | |
| PH12021550269A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
| PH12023552079A1 (en) | Cdk2 inhibitors and methods of using the same | |
| EA033236B1 (ru) | Новые производные пиразола в качестве ингибиторов nik | |
| MX371153B (es) | Nuevos compuestos como inhibidores de la cinasa inductora de nf-kb (nik). | |
| PH12021550743A1 (en) | Boron containing pde4 inhibitors | |
| MX2021008712A (es) | Derivados heterociclicos. | |
| PH12022551623A1 (en) | Substituted pyrazolo-pyrimidines and uses thereof | |
| EP3902536C0 (en) | Compositions containing 5-benzylaminosalicylic acid compounds for use in the treatment of neurodegenerative disorders in pets |